Australian laws and regulations limit the amount of information we can provide to the general public via our website. Our Consumer Medicine Information (CMI) leaflets are intended for patients who have been prescribed our products. They provide information on the safe and effective use of the prescription medicine. Our Product Information (PI) sheets are intended for healthcare professionals. They provide a summary of the essential scientific information for the safe and effective use of a prescription medicine.

Pain

DILAUDID® tablets and liquid

immediate release hydromorphone hydrochloride

DILAUDID®HP ampoules

MS CONTIN® tablets

modified release morphine sulfate

MS CONTIN® suspension

modified release morphine sulfate

MS MONO® capsules

modified release morphine sulfate

Norspan® Patch

transdermal buprenorphine matrix patch

ORDINE® oral solution

immediate release morphine hydrochloride

OxyContin® tablets

modified release oxycodone hydrochloride

OxyNorm® injection

immediate release oxycodone hydrochloride

SEVREDOL® tablets

immediate release morphine sulfate

TARGIN® tablets

modified release oxycodone and modified release naloxone hydrochloride dihydrate

® DILAUDID, MS CONTIN, MS MONO, NORSPAN, OXYCONTIN, OXYNORM, SEVREDOL and TARGIN are registered trade marks.
® ORDINE is a registered trade mark of Pfizer (Perth) Pty Ltd and is used under licence.

*Due to unforeseen manufacturing issues, DILAUDID® oral liquid (hydromorphone 1mg/mL) is unavailable. It is anticipated that supply will recommence in September 2017. If you are a patient, please speak with your doctor. Please call Mundipharma Medical Information (1800-188-009) for information on Mundipharma products.